(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes.
In a phase III trial…
After Hantavirus scare, Norovirus outbreak on another cruise ship sparks concern: How they differ from Covid-19, symptoms to know
After Hantavirus scare, Norovirus outbreak on another cruise ship sparks concern: How they differ from Covid-19, symptoms to know Source:...





